Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography

Coronary Artery Disease

Volumn 20, Issue 2, 2009, Pages 112-117

  Cavusoglu, Erdal ^a,b,d   Ruwende, Cyril ^c   Chopra, Vineet ^b   Yanamadala, Sunitha ^c   Eng, Calvin ^b   Pinsky, David J ^c   Marmur, Jonathan D ^a  

^a SUNY Downstate Medical Center   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Acute coronary syndrome; Asymmetric dimethylarginine; Biomarker; Myocardial infarction; Nitric oxide; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N(G),N(G) DIMETHYLARGININE; ARGININE; DRUG DERIVATIVE; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE;

ACUTE CORONARY SYNDROME; ADULT; AGED; AMINO ACID BLOOD LEVEL; ANGIOCARDIOGRAPHY; ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT REFERRAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; ST SEGMENT ELEVATION; STROKE; UNSTABLE ANGINA PECTORIS; BLOOD; KAPLAN MEIER METHOD; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RADIOGRAPHY; RISK ASSESSMENT; RISK FACTOR; TIME; UPREGULATION;

ACUTE CORONARY SYNDROME; AGED; ANGINA, UNSTABLE; ARGININE; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UP-REGULATION;

EID: 66349098445     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e328323982f     Document Type: Article

References (25)

1. Moncada S. The L-arginine: nitric oxide pathway, cellular transduction and immunological roles. Adv Second Messenger Phosphoprotein Res 1993; 28:97-99.
2. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327:524-526.
3. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20:2032-2037.
4. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842-1847.
5. Lundman P, Eriksson MJ, Stuhlinger M, Cooke JP, Hamsten A, Tornvall P. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 2001; 38:111-116.
6. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33:652-658.
7. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339:572-575.
8. Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997; 95:2068-2074.
9. Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care 2007; 30:1834-1839.
10. Lajer M, Tarnow L, Jorsal A, Teerlink T, Parving HH, Rossing P. Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2008; 31:747-752.
11. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358:2113-2117.
12. Mittermayer F, Krzyzanowska K, Exner M, Mlekusch W, Amighi J, Sabeti S, et al. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol 2006; 26:2536-2540.
13. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 2003; 24:1912-1919.
14. Krempl TK, Maas R, Sydow K, Meinertz T, Boger RH, Kahler J. Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J 2005; 26:1846-1851.
15. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005; 97:e53-e59.
16. Cavusoglu E, Chopra V, Gupta A, Clark LT, Eng C, Marmur JD. Usefulness of anemia in men as an independent predictor of two-year cardiovascular outcome in patients presenting with acute coronary syndrome. Am J Cardiol 2006; 98:580-584.
17. Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT, et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J 2006; 27:2300-2309.
18. Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001; 88: 1201-1203.
19. Bae SW, Stuhlinger MC, Yoo HS, Yu KH, Park HK, Choi BY, et al. Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am J Cardiol 2005; 95: 729-733.
20. McMurray J, Chopra M, Abdullah I, Smith WE, Dargie HJ. Evidence for oxidative stress in unstable angina. Br Heart J 1992; 68:454-457.
21. Aukrust P, Berge RK, Ueland T, Aaser E, Damas JK, Wikeby L, et al. Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. J Am Coll Cardiol 2001; 37:485-491.
22. Yokoyama M. Oxidant stress and atherosclerosis. Curr Opin Pharmacol 2004; 4:110-115.
23. Valgimigli M, Merli E, Malagutti P, Soukhomovskaia O, Cicchitelli G, Macri G, et al. Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress. Arch Biochem Biophys 2003; 420:255-261.
24. Sydow K, Munzel T. ADMA and oxidative stress. Atheroscler Suppl 2003; 4:41-51.
25. Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000; 87:99-105.